<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1713">
  <stage>Registered</stage>
  <submitdate>15/10/2007</submitdate>
  <approvaldate>15/10/2007</approvaldate>
  <nctid>NCT00544271</nctid>
  <trial_identification>
    <studytitle>Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.</studytitle>
    <scientifictitle>Phase IIIb Study to Evaluate Immunogenicity, Antibody Persistency and Reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX Vaccines Administered to Healthy Children Previously Primed With 3 Doses of DTPa Vaccine Compared to Placebo (HAVRIXÂ®JUNIOR)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>263855/035</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acellular Pertussis</healthcondition>
    <healthcondition>Tetanus</healthcondition>
    <healthcondition>Diphtheria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - INFANRIX
Other interventions - BOOSTRIX
Other interventions - HAVRIX

Other interventions: INFANRIX


Other interventions: BOOSTRIX


Other interventions: HAVRIX


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anti-diphtheria and anti-tetanus antibody concentration (1M, 15-18M &amp; 27-29M after vacc)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Occurrence of local injection site reactions (1M after vacc).</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Antibody concentration to all vaccine antigens (1M, 15-18M &amp; 27-29M after vacc),</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Solicited (Day 0-14) &amp; Unsolicited symptoms (Day 0-30),</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SAEs (full study).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female children between and including 18 -20 months of age at the time of the
             vaccination.

          -  Completed a primary vaccination course with DTPa (INFANRIX) vaccine at 2, 4, and 6
             months.

          -  Written informed consent obtained before study entry from the parents or guardians of
             the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>20</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the administration of the study vaccine dose, or
             planned use during the study period.

          -  Evidence of previous or intercurrent diphtheria, tetanus, or pertussis disease, or of
             vaccination against any of these diseases since completion of the primary course of
             DTPa (INFANRIX) vaccine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>720</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>GSK Investigational Site - Carlton</hospital>
    <postcode>3053 - Carlton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the immunogenicity, persistence of antibodies and reactogenicity of GSK
      Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX), when administered to subjects 18-20 months
      old, compared with not giving a booster DTP vaccine at 18-20 months. Study double blinded for
      the two DTP vaccines and single blinded for the control arm.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00544271</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>